Insider Transactions

INTERNATIONAL BUSINESS MACHINES CORP (IBM) Insider Transactions

Over the last 12 months, 20 INTERNATIONAL BUSINESS MACHINES CORP (IBM) insiders filed 171 SEC Form 4 transactions — $417.2K in open-market purchases ( 3 distinct buyers) and $0 in open-market sales. 0% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.

Recent Form 4 Filings Most recent 50 of 171 (1-year window)

Each row is a single Form 4 filing event for IBM, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.

Date Insider Title Type SEC Code Value Shares Price
2026-06-04 Fehring Nicolas A. VP, Controller Other G $0 400 $0.00
2026-03-31 Laguarta Ramon Grant A $30.5K 126 $242.39
2026-03-31 Brown Marianne Catherine Grant A $91.4K 377 $242.39
2026-03-31 Buberl Thomas Grant A $91.4K 377 $242.39
2026-03-31 FARR DAVID N Grant A $58.9K 243 $242.39
2026-03-31 Gorsky Alex Grant A $107.6K 444 $242.39
2026-03-31 HOWARD MICHELLE J Grant A $64.0K 264 $242.39
2026-03-31 LIVERIS ANDREW N Grant A $97.7K 403 $242.39
2026-03-31 MCNABB FREDERICK WILLIAM III Grant A $91.4K 377 $242.39
2026-03-31 Miebach Michael Grant A $91.4K 377 $242.39
2026-03-31 VOSER PETER R. Grant A $100.1K 413 $242.39
2026-03-31 WADDELL FREDERICK H Grant A $97.7K 403 $242.39
2026-03-31 ZOLLAR ALFRED W Grant A $91.4K 377 $242.39
2026-03-31 Pollack Martha E Grant A $58.9K 243 $242.39
2026-02-26 Robinson Anne Senior Vice President Grant $0 6,341 $0.00
2026-02-26 Robinson Anne Senior Vice President Grant $0 25,363 $0.00
2026-02-26 LAMOREAUX NICKLE JACLYN Senior Vice President Grant $0 6,285 $0.00
2026-02-26 LAMOREAUX NICKLE JACLYN Senior Vice President Grant $0 25,138 $0.00
2026-02-26 KRISHNA ARVIND Chairman, President & CEO Grant $0 22,518 $0.00
2026-02-26 KRISHNA ARVIND Chairman, President & CEO Grant $0 90,071 $0.00
2026-02-26 KAVANAUGH JAMES J Sr. VP and CFO Grant $0 10,364 $0.00
2026-02-26 KAVANAUGH JAMES J Sr. VP and CFO Grant $0 41,455 $0.00
2026-02-26 Fehring Nicolas A. VP, Controller Grant $0 2,844 $0.00
2026-02-26 Fehring Nicolas A. VP, Controller Grant $0 7,584 $0.00
2026-02-26 COHN GARY D Vice Chairman Grant $0 10,565 $0.00
2026-02-26 COHN GARY D Vice Chairman Grant $0 42,258 $0.00
2026-02-26 Thomas Robert David Senior Vice President Grant $0 10,565 $0.00
2026-02-26 Thomas Robert David Senior Vice President Grant $0 42,258 $0.00
2026-02-25 HOWARD MICHELLE J Buy $11.9K 50 $237.83
2026-02-25 Miebach Michael Buy $101.3K 434 $233.33
2026-02-21 COHN GARY D Vice Chairman Grant $0 2,725 $0.00
2026-02-21 COHN GARY D Vice Chairman Grant $386.4K 1,507 $256.42
2026-02-21 COHN GARY D Vice Chairman Grant $0 2,611 $0.00
2026-02-21 COHN GARY D Vice Chairman Grant $370.3K 1,444 $256.42
2026-02-21 COHN GARY D Vice Chairman Grant $0 2,246 $0.00
2026-02-21 COHN GARY D Vice Chairman Grant $318.7K 1,243 $256.42
2026-02-21 COHN GARY D Vice Chairman Grant $0 2,725 $0.00
2026-02-21 COHN GARY D Vice Chairman Grant $0 2,611 $0.00
2026-02-21 COHN GARY D Vice Chairman Grant $0 2,246 $0.00
2026-02-21 KAVANAUGH JAMES J Sr. VP and CFO Grant $0 3,380 $0.00
2026-02-21 KAVANAUGH JAMES J Sr. VP and CFO Grant $434.4K 1,694 $256.42
2026-02-21 KAVANAUGH JAMES J Sr. VP and CFO Grant $0 3,575 $0.00
2026-02-21 KAVANAUGH JAMES J Sr. VP and CFO Grant $459.5K 1,792 $256.42
2026-02-21 KAVANAUGH JAMES J Sr. VP and CFO Grant $0 2,877 $0.00
2026-02-21 KAVANAUGH JAMES J Sr. VP and CFO Grant $369.8K 1,442 $256.42
2026-02-21 KAVANAUGH JAMES J Sr. VP and CFO Grant $0 3,380 $0.00
2026-02-21 KAVANAUGH JAMES J Sr. VP and CFO Grant $0 3,575 $0.00
2026-02-21 KAVANAUGH JAMES J Sr. VP and CFO Grant $0 2,877 $0.00
2026-02-21 KRISHNA ARVIND Chairman, President & CEO Grant $0 5,166 $0.00
2026-02-21 KRISHNA ARVIND Chairman, President & CEO Grant $663.4K 2,587 $256.42

Showing the most recent 50 of 171 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.

Top Insider Buyers of IBM By dollar volume, 1-year window

  1. FARR DAVID N $304.0K
  2. Miebach Michael $101.3K
  3. HOWARD MICHELLE J $11.9K

Methodology & FAQ

How We Track IBM Insider Transactions

Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.

What is an SEC Form 4 filing for INTERNATIONAL BUSINESS MACHINES CORP?

Form 4 is a transaction-level disclosure that corporate insiders — officers, directors, and beneficial owners of more than 10% of a registered class of equity securities — must file with the SEC within two business days of any change in their beneficial ownership of INTERNATIONAL BUSINESS MACHINES CORP (IBM) shares.

What is a Rule 10b5-1 trading plan?

Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.

How is "insider buying" different from a stock grant or option exercise?

An insider buy (SEC transaction code P) is an open-market purchase of INTERNATIONAL BUSINESS MACHINES CORP (IBM) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.

How recent is the data?

Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.